SUNDAE/ Semanat / Semafull
by Eris Lifesciences / Natco Pharma · DCGI approved February 2026 (CDSCO)
| Active ingredient | Semaglutide (GLP-1 receptor agonist) |
| Indication | Type 2 Diabetes + Obesity |
| Manufacturer | Eris Lifesciences Ltd (with Natco Pharma) |
| DCGI status | Approved February 2026 (CDSCO) |
| Price (MRP) | ₹220 per shot Globally lowest entry price for any semaglutide product. Vial format suited to clinic/hospital administration; pen device launched April 2026. |
| Format | Multi-dose vial + Pen |
| Prescription | Schedule H — required |
How SUNDAE compares
SUNDAE has the lowest entry price of any semaglutide product in India — and globally — at ₹220 per shot. The multi-dose vial format is best suited for hospital and clinic settings where nurses administer doses; a pen device launched April 2026 for self-administration. Semanat and Semafull are sister brand names by Eris/Natco's commercial partners.
About Eris Lifesciences / Natco Pharma
Natco Pharma developed the formulation; Eris Lifesciences leads the commercialisation in India through its endocrinologist and diabetologist sales force. The Eris–Natco partnership is one of the most aggressively-priced Indian generic plays, driving the broader market price floor.
GLP-1 Check is informational, not a medical diagnosis. Semaglutide is a Schedule H drug in India and requires a prescription from a registered medical practitioner. Always consult a qualified physician before starting any treatment.